Mirador Therapeutics announces partnership to acquire Kira drug, positioning it against Tavneos

Mirador Therapeutics, a San Diego‑based biotech focused on immune diseases and backed by more than $650 million in venture capital, has disclosed a new element of its development pipeline.

The company said it has reached a worldwide agreement to obtain a drug candidate from Kira Therapeutics. The deal is intended to give Mirador a product that can compete directly with the existing therapy Tavneos.

Details of the drug’s target, clinical stage, or financial terms were not provided in the announcement. The move signals Mirador’s effort to expand its portfolio and challenge established treatments in the immune‑disease market.